- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04580368
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials (Nof1)
Study Overview
Detailed Description
This is a protocol for the development of personalized treatments from bench to bedside for rare CF mutations. The protocol will start with the current FDA-approved CFTR modulators and continue to add newly developed CF drug therapies to the potential treatment testing options as they are approved for market. This is a single-center study enrolling subjects with rare CFTR variants who are prescribed CFTR modulators by their treating physician. This decision may be based on the patient's genotype (e.g., a patient with a CFTR mutation known to respond to drug) or based on preclinical HNE model testing; regardless, the decision to start a modulator is made by the subject's physician, not by the study team.
The N-of-1 design includes a basic research component using nasal brushings which will be expanded in the HNE Core Lab and tested with CFTR modulating drug therapies. Based on the HNE culture's reactivity to the tested CFTR modulating drugs, an N-of-1 trial will be initiated to test if this translates to therapeutic benefit.
The CFTR modulating drugs that are currently FDA approved and will be tested in this study include ivacaftor and the combination drugs orkambi (ivacaftor/lumacaftor), symdeko (ivacaftor/tezacaftor), and trikafta (elexacaftor/tezacaftor/ivacaftor). All will be used in clinically prescribed dosages and within the FDA approved age ranges.
For HNE testing, subjects will fall into two pools. The first will have already undergone HNE model testing with positive results. These subjects will proceed directly to N-of-1 testing without additional ex vivo studies. The second group will have been referred for N-of-1 testing based on their CFTR genotype, having not previously undergone HNE testing. This group will have HNEs harvested at the initial visit, and HNE testing will occur in parallel to N-of-1 testing.
For the N-of-1 portion of this trial, subjects will undergo a 14-day run-in period, followed by an observational 28-day block of non-treatment. This will be followed with a 14-day washout period, and then by a 28-day block of modulator treatment, with a final 14-day washout period and a 14-day follow-up period before study completion. Repeated assessments will occur at the beginning and end of each 28-day block. Participants will therefore be on study for approximately 112 days. This protocol will remain open indefinitely to develop treatment options for patients with new and not well defined forms of Cystic Fibrosis and CFTR disorders.
At this time, CFTR modulator drugs can only be filled in specialty pharmacies, and is not on formulary at CCHMC. While the development of a specialty pharmacy was in process at CCHMC, this progress has halted due to the COVID-19 pandemic. Because the drugs cannot be filled internally, the Investigational Drug Service is unable to dispense them or provide placebo for blinded studies. Because understanding the individual response to these compounds and the relationship of that response to HNE models is critical, this study will move forward in an open-label fashion. If the CCHMC specialty pharmacy is successfully opened, we anticipate a revision to modify this protocol to a double-blinded, placebo-controlled crossover, however, this is not currently possible. This change has been discussed with the funding agency (NIH / NIDDK), who are in agreement.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: John Brewington, MD
- Phone Number: 513-736-0614
- Email: John.Brewington@cchmc.org
Study Contact Backup
- Name: Rory OShaughnessy, MPH
- Phone Number: 513-803-0024
- Email: Rory.OShaughnessy@cchmc.org
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45203
- Recruiting
- CCHMC
-
Contact:
- John Brewington
- Phone Number: 513-803-1548
- Email: John.Brewington@cchmc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent (and assent when applicable)
- Willing and able to adhere to the study visit schedule and protocol requirements
Male or Female ≥6 years old and within the FDA-approved range for the proposed modulator drug
- Ivacaftor: ≥4 months old
- Lumacaftor/Ivacaftor: 2 years old
- Tezacaftor/Ivacaftor: 12 years old
- Elexacaftor/Tezacaftor/Ivacaftor: ≥12 years old
- At least one rare CFTR variant (incidence of <5% of the CF population)
Documentation of a CF diagnosis as evidenced by one or more clinical features of CF plus at least one of the following:
- Sweat Chloride ≥60mmol/L by quantitative pilocarpine iontophoresis
- Two mutations in the CFTR gene
- Abnormal nasal potential difference (NPD) testing supportive of a CF diagnosis
- FEV1 > 50% predicted for age
- Stable chronic CF therapies with no changes in >28 days (except for chronic cycled inhaled antibiotics such as tobramycin)
- Prescribed CFTR modulator by a licensed physician
- No contraindication to treatment with the selected drug at the time of treatment initiation
Exclusion Criteria:
- Presence of any condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient and/or quality of the data
For women of child bearing potential:
- Positive pregnancy test or known pregnancy at Visit 1
- Lactating
- Unwilling to practice a medically acceptable form of contraception (acceptable forms include abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent), unless surgically sterilized or postmenopausal during the study
- BMI < 10th percentile for age (if <18 years old) or < 20kg/m2 (if ≥18 years old)
- FEV1 ≤ 50% predicted for age
- Growth of CF pathogens from sputum cultures that are associated with unstable disease (e.g., nontuberculous mycobacteria, Burkholderia spp) within six months of enrollment
- Concomitant use of CYP3A inducers or inhibitors (e.g., voriconazole, fluconazole, rifampin) or prednisone (>20mg daily)
Concomitant conditions:
- Poorly controlled diabetes mellitus (HbA1c >8.5 or glucosuria as noted below)
- Advanced CF liver disease (cirrhosis with portal hypertension, ascites, or abnormal liver laboratory testing as noted below)
- End stage renal disease
- History of organ transplantation
- Additional medical conditions that in the opinion of the Investigator place the patient at risk of participation or may impact the patient's ability to complete the trial (e.g., uncontrolled depression, anxiety disorder, poor adherence to CF therapies, active ABPA)
Any of the following abnormal laboratory values at the Screening Visit:
- CBC
- WBC >15,000 K/mcL or ANC <1,500 K/mcL
- Hemoglobin <10 gm/dL
- Platelets <50,000 K/mcL
- Chemistries
- >2+ Glucosuria
- Clinically significant abnormalities as assessed by the Investigator
- Glomerular filtration rate ≤50 mL/min/1.73 m2 (calculated by the Counahan-Barratt equation)
- Hepatic Function Testing / Coagulation Testing
- ≥3 × upper limit of normal (ULN) aspartate aminotransferase (AST)
- ≥3 × ULN alanine aminotransferase (ALT)
- ≥3 × ULN gamma-glutamyl transpeptidase
- Total or direct bilirubin >2 × ULN
- INR > 1.5 x ULN
- Positive pregnancy test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CFTR modulator or other therapies
CFTR modulator or active therapy
|
Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ppFEV1
Time Frame: 16 weeks
|
Absolute change in ppFEV1 of 5% or greater
|
16 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N of 1_2019-0545
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on CFTR Modulators
-
Indiana UniversityCystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Bone Loss | Muscle LossUnited States
-
Hospices Civils de LyonActive, not recruiting
-
Societe Francaise de la MucoviscidoseRecruitingCystic Fibrosis in ChildrenFrance
-
National Center for Research Resources (NCRR)University of North CarolinaCompleted
-
Universidad Europea de MadridWithdrawnCystic Fibrosis in ChildrenSpain
-
National Institute of Diabetes and Digestive and...University of FloridaCompleted
-
Children's Hospital Medical Center, CincinnatiThe Hospital for Sick Children; University of Wisconsin, Madison; University...Active, not recruiting
-
Charite University, Berlin, GermanyHannover Medical School; Heidelberg University; University of GiessenRecruiting
-
University of RochesterCompletedFunctional Disorder of IntestineUnited States
-
Forest LaboratoriesCompletedMajor Depressive DisorderUnited States